About Taj Oncology
Taj Oncology is a company based in Mumbai (India) founded in 2009. Taj Oncology offers products and services including Imatinib Mesylate and Hydroxyurea.
- Headquarter Mumbai, India
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
- Legal Name Taj Pharmaceuticals Limited
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$581.39 K (USD)42.79as on Mar 31, 2023
-
Net Profit
$11.63 K (USD)19.54as on Mar 31, 2023
-
EBITDA
-$162.2 K (USD)-608.3as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Taj Oncology
Taj Oncology offers a comprehensive portfolio of products and services, including Imatinib Mesylate and Hydroxyurea.
Imatinib Mesylate is utilized to treat certain types of leukemia and is produced as a protein-tyrosine kinase inhibitor that inhibits abnormal cell proliferation.
Hydroxyurea is employed to treat cancers like melanoma and leukemia and is manufactured by interfering with cell replication to reduce tumor growth.
Funding Insights of Taj Oncology
Detailed funding history for Taj Oncology
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Taj Oncology
Investment portfolio details for Taj Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Taj Oncology
Detailed financials for Taj Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Taj Oncology Comparisons
Peer comparison for Taj Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Taj Oncology
Detailed competitors of Taj Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Taj Oncology
Complete news archive for Taj Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Taj Oncology
Taj Oncology was founded in 2009.
Taj Oncology is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Annual revenue of Taj Oncology is $581.39K as on Mar 31, 2023.
Taj Oncology is identified as a leading manufacturer of generic oncology products and biosimilars, with a broad portfolio focused on providing affordable, high-quality treatments for cancer. Efforts are made to reduce healthcare costs and improve patient quality of life through innovative pharmaceutical offerings. The company emphasizes research and development to discover new therapies and maintains collaborations for advanced cancer care, while ensuring compliance with regulatory standards.
Taj Oncology offers Imatinib Mesylate and Hydroxyurea.